SEC Form 4 · accession 0001445064-15-000097
Keenova Therapeutics plc
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Peter G Edwards
Officer — Sr. VP & General Counsel
Period of report
May 27, 2015
Accepted (ET)
May 29, 2015 · 5:33 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001567892
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Ordinary Shares | May 27, 2015 | M | 3,994 | $29.89 | A | 21,287 | D | |
| Ordinary Shares | May 27, 2015 | M | 7,007 | $31.12 | A | 28,294 | D | |
| Ordinary Shares | May 27, 2015 | M | 5,549 | $33.67 | A | 33,843 | D | |
| Ordinary Shares | May 27, 2015 | M | 6,192 | $41.73 | A | 40,035 | D | |
| Ordinary Shares | May 27, 2015 | M | 3,036 | $51.35 | A | 43,071 | D | |
| Ordinary SharesF1 | May 27, 2015 | S | 25,778 | $127.90 | D | 17,293 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy) | $29.89 | May 27, 2015 | M | 3,994 | D | Jun 28, 2013 | May 31, 2020 | Ordinary Shares | 3,994 | 0 | D |
| Share Options (Right to Buy) | $31.12 | May 27, 2015 | M | 7,007 | D | Dec 1, 2013 | Nov 30, 2020 | Ordinary Shares | 7,007 | 0 | D |
| Share Options (Right to Buy) | $33.67 | May 27, 2015 | M | 5,549 | D | Dec 1, 2013 | Nov 30, 2021 | Ordinary Shares | 5,549 | 2,777 | D |
| Share Options (Right to Buy) | $41.73 | May 27, 2015 | M | 6,192 | D | Dec 3, 2013 | Dec 2, 2022 | Ordinary Shares | 6,192 | 6,192 | D |
| Share Options (Right to Buy) | $51.35 | May 27, 2015 | M | 3,036 | D | Jan 2, 2015 | Jan 2, 2024 | Ordinary Shares | 3,036 | 9,108 | D |
Explanation of responses
- F1The price represents a weighted average. The shares were sold in multiple transactions at prices ranging from $127.90 to $127.92, inclusive. Mr. Edwards will provide, upon request of the SEC staff, Mallinckrodt plc or a shareholder of Mallinckrodt plc complete information regarding the number of shares sold at each price within the range.